+ All Categories
Home > Government & Nonprofit > What’s in a name - biosimilars?

What’s in a name - biosimilars?

Date post: 13-Jun-2015
Category:
Upload: tga-australia
View: 751 times
Download: 0 times
Share this document with a friend
Description:
The presentation was given by the TGA at the 2014 ARCS Scientific Congress, and covers the definition of the term 'biosomilars' and its features
Popular Tags:
13
Click icon to What’s in a name – biosimilars? Kevin Grant Section Head, Office of Laboratories & Scientific Services, Monitoring & Compliance Group, TGA ARCS Scientific Congress 2014 10 September 2014
Transcript
Page 1: What’s in a name - biosimilars?

Click icon to add picture

What’s in a name – biosimilars?

Kevin Grant

Section Head, Office of Laboratories & Scientific Services,Monitoring & Compliance Group, TGA

ARCS Scientific Congress 2014

10 September 2014

Page 2: What’s in a name - biosimilars?

2

What is a biosimilar?A biosimilar is a “copy” version of an approved biological medicine with demonstrated similarity in physicochemical, biological and immunological characteristics, efficacy and safety, based on a comprehensive comparability study.

Biosimilars are variously termed:

• Similar Biotherapeutic Products (WHO)

• Similar Biological Medicinal Products (EU/TGA)

• “biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed biological reference product” (US FDA)

• follow-on biologics (PMDA, Japan) and

• subsequent entry biologics (Health Canada).

What’s in a name – biosimilars?

Page 3: What’s in a name - biosimilars?

3

Biosimilar ≠ generic

What’s in a name – biosimilars?

Page 4: What’s in a name - biosimilars?

4

1.Size

What’s in a name – biosimilars?

Asprin vs IgGFrom: Kozlowski et al NEJM 2011;365:385-388

Page 5: What’s in a name - biosimilars?

5

1. Size

2. Complexity – 4 levels of structure

Biosimilar

What’s in a name – biosimilars?

Page 6: What’s in a name - biosimilars?

6

1. Size

2. Complexity - glycosylation

What’s in a name – biosimilars?

Page 7: What’s in a name - biosimilars?

7

Variability – e.g. EPO • Mass = 27948±285 deglycosylated 18240±4

• 2 disulphide bonds• 3 N-glycosylation • 2 O-glycosylation sites• Many types of glycans• C-terminal truncation

Even the most controlled biotechnological process produces a spectrum of 100 000s of molecules – all having different activity, half-life and potential to induce an immune reaction.

What’s in a name – biosimilars?

Page 8: What’s in a name - biosimilars?

8

1. Size

2. Complexity

3. Variability

Biosimilar ≠ generic

Comparable ≠ bioequivalent

What’s in a name – biosimilars?

Page 9: What’s in a name - biosimilars?

9

Naming safety • Information• Warning• Clarity

What’s in a name – biosimilars?

Page 10: What’s in a name - biosimilars?

10

Naming safety For biosimilars:• Identify reference product• Distinguish from other biosimilars• Clarify use

What’s in a name – biosimilars?

Page 11: What’s in a name - biosimilars?

11

Naming safety TGA biosimilar naming policy:• ABN of reference product• Biosimilar identifier based on INN• Linked to advice in PI

What’s in a name – biosimilars?

Page 12: What’s in a name - biosimilars?

12

Thank you!

What’s in a name – biosimilars?

Page 13: What’s in a name - biosimilars?

Recommended